This week, these five stocks have the worst ratings in Sales Growth, one of the eight Fundamental Categories on Portfolio Grader.
Discovery Laboratories (NASDAQ:DSCO) is a biotechnology company focused on developing products for the treatment of respiratory disease. DSCO also gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of DSCO stock.
NovaGold Resources (AMEX:NG) explores and develops mineral properties in North America. NG also gets an F in Equity. Shares of the stock have declined 41.9% since January 1. The stock currently has a trailing PE Ratio of 228.2. For more information, get Portfolio Grader’s complete analysis of NG stock.
Sunesis Pharmaceuticals (NASDAQ:SNSS) is a clinical-stage biopharmaceutical Company which focuses on the discovery, development and commercialization of novel small molecule therapeutics for oncology. SNSS gets F’s in Earnings Growth, Equity, and Cash Flow as well. For more information, get Portfolio Grader’s complete analysis of SNSS stock.
AVEO (NASDAQ:AVEO) engages in discovering, developing, and commercializing targeted cancer therapies using its Human Response Platform. AVEO also gets F’s in Earnings Growth, Earnings Momentum, Equity, Cash Flow, and Operating Margin Growth. Since January 1, AVEO has fallen 54.2%. This is worse than the Nasdaq, which has seen a 14.7% increase over the same period. For more information, get Portfolio Grader’s complete analysis of AVEO stock.
Green Bankshares (NASDAQ:GRNB) is the holding company for Greene County Bank and Cumberland Bank. GRNB gets F’s in Earnings Momentum and Cash Flow as well. For more information, get Portfolio Grader’s complete analysis of GRNB stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.